Stiff-person Syndrome - PubMed (original) (raw)
Stiff-person Syndrome
Olavo M. Vasconcelos et al. Curr Treat Options Neurol. 2003 Jan.
Abstract
Stiff-person syndrome (SPS) is a progressive neurologic disorder characterized by 1) stiffness that is prominent in axial muscles, with co-contraction of agonist and antagonist muscles; 2) sudden episodic spasms; and 3) absence of another disease that causes similar symptoms. The diagnosis of SPS is based on clinical grounds and requires a high degree of suspicion. The diagnosis is, however, aided by electromyography, which demonstrates motor unit firing at rest simultaneously from the agonist and antagonist muscles, and by high serum titers of antibodies against glutamic acid decarboxylase (GAD), the rate-limiting enzyme for the synthesis of gamma-aminobutyric acid (GABA), which is the brain's main inhibitory neurotransmitter. The reduced GABA level in the brain and cerebrospinal fluid explains the patients' stiffness and justifies the clinical improvement observed by drugs enhancing GABAergic transmission. The association of SPS with other autoimmune disorders or autoantibodies, the intrathecal GAD-specific immunoglobulin G antibody synthesis, and the suppression of GABA by the patient's antibodies supports the autoimmune nature of SPS and justifies the use of immunotherapies. At present, GABA-enhancing agents, such as benzodiazepines, valproate, vigabatrin, tiagabine, gabapentin, and baclofen, provide symptomatic relief. Plasmapheresis, steroids, and periodic intravenous immunoglobulin infusions provide additional and lasting benefit. In this article, the treatment options for patients with SPS are discussed based on the authors' experience and that of others. The beneficial effects from the first controlled study conducted in SPS using intravenous immunoglobulin are presented.
Similar articles
- Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.
Dalakas MC. Dalakas MC. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 14;10(3):e200109. doi: 10.1212/NXI.0000000000200109. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37059468 Free PMC article. Review. - The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid.
Levy LM, Dalakas MC, Floeter MK. Levy LM, et al. Ann Intern Med. 1999 Oct 5;131(7):522-30. doi: 10.7326/0003-4819-131-7-199910050-00008. Ann Intern Med. 1999. PMID: 10507962 Review. - The stiff-person syndrome. Case report.
Piovano C, Piattelli M, Spina T, Iervese G, Bosco G. Piovano C, et al. Minerva Anestesiol. 2002 Nov;68(11):861-5. Minerva Anestesiol. 2002. PMID: 12538969 - Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.
Dalakas MC. Dalakas MC. Neurotherapeutics. 2022 Apr;19(3):832-847. doi: 10.1007/s13311-022-01188-w. Epub 2022 Jan 27. Neurotherapeutics. 2022. PMID: 35084720 Free PMC article. Review. - Association of stiff-person syndrome with autoimmune endocrine diseases.
Lee YY, Chen IW, Chen ST, Wang CC. Lee YY, et al. World J Clin Cases. 2019 Oct 6;7(19):2942-2952. doi: 10.12998/wjcc.v7.i19.2942. World J Clin Cases. 2019. PMID: 31624742 Free PMC article.
Cited by
- Current therapies for neuromuscular manifestations of paraneoplastic syndromes.
Rosenfeld MR, Dalmau J. Rosenfeld MR, et al. Curr Neurol Neurosci Rep. 2006 Jan;6(1):77-84. doi: 10.1007/s11910-996-0012-0. Curr Neurol Neurosci Rep. 2006. PMID: 16469274 - Levetiracetam in stiff-person syndrome.
Sechi G, Barrocu M, Piluzza MG, Cocco GA, Deiana GA, Sau GF. Sechi G, et al. J Neurol. 2008 Nov;255(11):1721-5. doi: 10.1007/s00415-008-0007-7. Epub 2008 Sep 3. J Neurol. 2008. PMID: 18769864 Clinical Trial. - Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.
Dalakas MC. Dalakas MC. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 14;10(3):e200109. doi: 10.1212/NXI.0000000000200109. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37059468 Free PMC article. Review. - GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions.
Tsiortou P, Alexopoulos H, Dalakas MC. Tsiortou P, et al. Ther Adv Neurol Disord. 2021 Mar 30;14:17562864211003486. doi: 10.1177/17562864211003486. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33854562 Free PMC article. Review.
References
- Mov Disord. 1997 Nov;12(6):1060-3 - PubMed
- Arch Neurol. 1980 Sep;37(9):600-1 - PubMed
- JAMA. 1966 Jan 17;195(3):222-4 - PubMed
- Neurology. 1981 Sep;31(9):1162-3 - PubMed
- Ther Apher. 2001 Feb;5(1):64-7 - PubMed
LinkOut - more resources
Full Text Sources